Research Study Links SARS-CoV-2 to Guillain-Barre Syndrome

Overview of the Study

A recent study published in the journal Brain investigates the potential connection between SARS-CoV-2 and Guillain-Barre syndrome (GBS). Following SARS-CoV-2 infections, over 90 cases of patients experiencing central and peripheral neurological disorders, including GBS, have been documented by medical professionals.

Understanding Guillain-Barre Syndrome

GBS is a rare autoimmune condition in which the immune system attacks the nerves, leading to muscle weakness and potentially paralysis. This disorder is often triggered by acute viral or bacterial infections, similar to the increased GBS cases observed during the Zika virus pandemic of 2015-2016.

Study Cohort and Methodology

The cohort study utilizes data from the International GBS Outcome Study, which includes patients from China, Denmark, France, Greece, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. The researchers analyzed data from 49 GBS patients admitted between January 30, 2020, and May 30, 2020. Among these, 11 patients (22%) had either a confirmed or probable SARS-CoV-2 infection. Notably, nine of these patients did not have any prior infections associated with GBS, while two had evidence of a recent infection with Campylobacter jejuni.

Findings Related to Symptoms and Inflammatory Markers

The 11 patients with GBS exhibited facial palsy and a demyelinating variant of the syndrome. The study aimed to assess whether SARS-CoV-2 could be a potential trigger for GBS or if the reported cases were merely coincidental. At the time of hospital admission, 73% of the GBS patients with COVID-19 had elevated inflammatory markers and met the diagnostic criteria for both GBS and COVID-19.

Conclusions and Future Research Directions

Despite these findings, researchers did not observe an increase in GBS cases during the SARS-CoV-2 pandemic compared to previous years. The results align with earlier studies, suggesting that the occurrence of GBS after SARS-CoV-2 infection is rare. The authors conclude that a strong association between GBS and COVID-19 is unlikely, recommending a case-control study to further investigate any potential causal relationship.

Reference

Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain (London, England: 1878). Published online 2021. doi:10.1093/brain/awab279

Image by Gerd Altmann from Pixabay